Stifel raises Mirum Pharmaceuticals stock price target on approvals

Mirum Pharmaceuticals (MIRM) reported positive Phase 3 results for LIVMARLI in treating cholestatic pruritus, meeting primary and secondary endpoints. The trial showed significant reductions in itch severity and bile acids. Mirum plans a U.S. regulatory filing in 2027. Analysts have mixed views, with a $184 price target but concerns over financials and technicals.

Mirum Pharmaceuticals reported that its drug maralixibat met the primary endpoint in the Phase 3 EXPAND trial, showing significant improvement in cholestatic pruritus. All secondary endpoints were also met, including reductions in serum bile acids. The company plans to submit a U.S. supplemental NDA in the first half of 2027. According to the company, safety data were consistent with prior experience.

Mirum Pharmaceuticals, Inc. (MIRM) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. Announcement of Data from the Phase 3 EXPAND Study of LIVMARLI (maralixibat) in Ultra-Rare Cholestatic Liver Diseases On October 12, 2026, Mirum Pharmaceuticals, Inc. (the “Company”) announced topline results from the Phase 3 EXPAND study evaluating LIVMAR

Morgan Stanley raised its price target for Mirum Pharmaceuticals (MIRM) to $152 from $137, citing positive Phase 3 study data and increased confidence in $1B peak sales for Livmarli. Micron (MU) shares fell 4% amid competition concerns, but Cavenagh Research upgraded it to Strong Buy with a $2,577 target, citing contractual pricing protections and strong financial results.

Mirum Pharmaceuticals' Livmarli showed success in a Phase III trial for treating itch in rare liver diseases, meeting all endpoints. The drug reduced itch scores and blood bile acid levels significantly. Mirum plans to submit an sNDA in 2027, potentially expanding Livmarli's label. Analysts project $876m in sales by 2032. Livmarli is currently FDA-approved for two rare liver conditions.

Baird reiterated an Outperform rating and $130 price target for Mirum Pharmaceuticals (MIRM) after positive Phase 3 trial results for maralixibat. The study met primary and secondary endpoints, with 50% of patients having biliary atresia. The company reported 44% revenue growth over the last year and is valued at $5.41 billion. Analysts revised earnings upwards, with price targets ranging from $118 to $195.